John Libbey Eurotext

Topiramate and temporal lobe epilepsy: an open-label study Volume 14, issue 2, June 2012


See all figures

Institute of Neurology, University Magna Græcia, Catanzaro, Department of Neuroscience, Neurology Division, Annunziata Hospital, Cosenza, Institute of Neurological Sciences, National Research Council, Cosenza, Italy

Purpose. To evaluate the efficacy and tolerability of topiramate (TPM) as monotherapy for patients with temporal lobe epileptic seizures based on an observational study. Methods. We evaluated 41 patients (20 female, mean age 54+18 years) with temporal lobe epilepsy (TLE) referred to the Epilepsy Unit, University of Catanzaro, Italy. Patients received TPM as monotherapy directly or after having taken other antiepileptic drugs. Seizure frequency changes and adverse events were recorded. Follow-up was conducted for a period of at least two years after treatment. Results. Patients received TPM, 50-600 mg/day, de novo ( n=29) or initially as add-on therapy before the switch ( n=12). In total, 28 of 41 patients achieved seizure freedom, whereas 10 showed a ≥50% reduction of seizure frequency. Two patients did not respond well and one patient discontinued TPM due to adverse effects. Conclusions. Our results confirm that TPM as either monotherapy or add-on therapy at doses of 50-600 mg/day effectively reduces seizure frequency in TLE. TPM is particular effective and very well tolerated in patients with mild TLE.